Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker CASIF
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| May 18, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | ETP Global III Fund L.P. | 20.00M | 49.3% | SCHEDULE 13D/A ↗ |
| May 18, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | HE Family GRAT | 100,000 | 0.5% | SCHEDULE 13D/A ↗ |
| May 18, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Etp Biohealth III Fund, L.P. | 300,000 | 1.5% | SCHEDULE 13D/A ↗ |
| May 18, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | ETP Global Fund L.P. | 753,234 | 3.7% | SCHEDULE 13D/A ↗ |
| May 18, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Emerging Technology Partners, LLC | 21.10M | 52.0% | SCHEDULE 13D/A ↗ |
| May 18, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Huiying Memorial Foundation | 637,644 | 3.1% | SCHEDULE 13D/A ↗ |
| May 18, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | WEI-WU HE, Ph.D. | 23.99M | 58.8% | SCHEDULE 13D/A ↗ |
| Mar 23, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | ETP Global III Fund L.P. | 15.00M | 42.2% | SCHEDULE 13D/A ↗ |
| Mar 23, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | HE Family GRAT | 100,000 | 0.5% | SCHEDULE 13D/A ↗ |
| Mar 23, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Etp Biohealth III Fund, L.P. | 300,000 | 1.5% | SCHEDULE 13D/A ↗ |
| Mar 23, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | ETP Global Fund L.P. | 753,234 | 3.7% | SCHEDULE 13D/A ↗ |
| Mar 23, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Emerging Technology Partners, LLC | 16.10M | 45.3% | SCHEDULE 13D/A ↗ |
| Mar 23, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Huiying Memorial Foundation | 637,644 | 3.1% | SCHEDULE 13D/A ↗ |
| Mar 23, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | WEI-WU HE, Ph.D. | 18.99M | 53.0% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Bong Y. Koh | 1.99M | 9.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Nimish Shah | 1.99M | 9.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CASIF CASI Pharmaceuticals, Inc. | VHCP Management EG, LLC | 1.99M | 9.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CASIF CASI Pharmaceuticals, Inc. | VHCP Management III, LLC | 1.99M | 9.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners EG, L.P. | 1.99M | 9.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CASIF CASI Pharmaceuticals, Inc. | VHCP Co-Investment Holdings III, LLC | 1.99M | 9.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners III, L.P. | 1.99M | 9.2% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | CASIF CASI Pharmaceuticals, Inc. | James Tananbaum | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Foresite Capital Management VI LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Foresite Capital Fund VI LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 10, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | ETP Global Fund III L.P. | 10.00M | 32.7% | SCHEDULE 13D/A ↗ |
| Feb 10, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | HE Family GRAT | 100,000 | 0.5% | SCHEDULE 13D/A ↗ |
| Feb 10, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Etp Biohealth III Fund, L.P. | 300,000 | 1.5% | SCHEDULE 13D/A ↗ |
| Feb 10, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | ETP Global Fund L.P. | 753,234 | 3.7% | SCHEDULE 13D/A ↗ |
| Feb 10, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Emerging Technology Partners, LLC | 1.10M | 5.3% | SCHEDULE 13D/A ↗ |
| Feb 10, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Huiying Memorial Foundation | 637,644 | 3.1% | SCHEDULE 13D/A ↗ |
| Feb 10, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | WEI-WU HE, Ph.D. | 13.97M | 45.4% | SCHEDULE 13D/A ↗ |
| Jan 29, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | ETP Global Fund III L.P. | 5.00M | 19.6% | SCHEDULE 13D/A ↗ |
| Jan 29, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | HE Family GRAT | 100,000 | 0.5% | SCHEDULE 13D/A ↗ |
| Jan 29, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Etp Biohealth III Fund, L.P. | 300,000 | 1.5% | SCHEDULE 13D/A ↗ |
| Jan 29, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | ETP Global Fund L.P. | 753,234 | 3.7% | SCHEDULE 13D/A ↗ |
| Jan 29, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Emerging Technology Partners, LLC | 1.10M | 5.3% | SCHEDULE 13D/A ↗ |
| Jan 29, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Huiying Memorial Foundation | 637,644 | 3.1% | SCHEDULE 13D/A ↗ |
| Jan 29, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | WEI-WU HE, Ph.D. | 8.97M | 34.8% | SCHEDULE 13D/A ↗ |
| Jan 20, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Zhou Quan | 992,638 | 4.8% | SCHEDULE 13D/A ↗ |
| Jan 20, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Ho Chi Sing | 915,850 | 4.5% | SCHEDULE 13D/A ↗ |
| Jan 20, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | IDG-Accel China Growth Fund GP III Associates Ltd. | 915,850 | 4.5% | SCHEDULE 13D/A ↗ |
| Jan 20, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | IDG-Accel China Growth Fund III Associates L.P. | 915,850 | 4.5% | SCHEDULE 13D/A ↗ |
| Jan 20, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | IDG-Accel China III Investors L.P. | 915,850 | 4.5% | SCHEDULE 13D/A ↗ |
| Jan 20, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | IDG-Accel China Growth Fund III L.P. | 915,850 | 4.5% | SCHEDULE 13D/A ↗ |
| Jan 20, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Kuiguang Niu | 1.02M | 5.0% | SCHEDULE 13D/A ↗ |
| Jan 20, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Jingbo Wang | 1.02M | 5.0% | SCHEDULE 13D/A ↗ |
| Jan 20, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Dongliang Lin | 1.02M | 5.0% | SCHEDULE 13D/A ↗ |
| Jan 20, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Jianguang Li | 1.02M | 5.0% | SCHEDULE 13D/A ↗ |
| Jan 20, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Zhuhai Hexie Zhiyuan Management Consulting Co., Ltd. | 1.02M | 5.0% | SCHEDULE 13D/A ↗ |
| Jan 20, 2026 | SCHEDULE 13D/A (amended) | CASIF CASI Pharmaceuticals, Inc. | Xizang Hexie Enterprise Management Co., Ltd. | 1.02M | 5.0% | SCHEDULE 13D/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:36 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances